Research Article
Assessment of Atrial Conduction Times in Patients with Newly Diagnosed Parkinson’s Disease
Table 1
Baseline demographic and clinical data of the study patients.
| | Characteristics | PD () | Control () | value |
| | Age, years | 68.1 ± 10.4 | 67.2 ± 13.5 | 0.819 | | Male, n (%) | 36 (71) | 16 (52) | 0.135 | | Hyperlipidemia, n (%) | 12 (24) | 8 (26) | 0.816 | | DM, n (%) | 8 (16) | 5 (16) | 0.958 | | Hypertension, n (%) | 14 (27) | 11 (35) | 0.604 | | Smoking, n (%) | 9 (18) | 4 (13) | 0.796 | | BMI (kg/m2) | 23.5 ± 2.7 | 23.0 ± 2.5 | 0.356 | | BSA (m2) | 1.94 ± 0.1 | 1.93 ± 0.12 | 0.659 |
| | Medications | | | | | ASA, n (%) | 6 (12) | 5 (16) | 0.820 | | ACEI, n (%) | 5 (10) | 5 (16) | 0.617 | | ARB, n (%) | 5 (10) | 7 (23) | 0.206 | | Calcium channel blocker, n (%) | 7 (14) | 5 (16) | 0.765 | | Diuretic, n (%) | 7 (14) | 8 (25) | 0.281 | | Statin, n (%) | 8 (16) | 6 (19) | 0.900 | | OAD, n (%) | 5 (10) | 5 (16) | 0.617 | | Insulin, n (%) | 4 (8) | 3 (10) | 0.773 | | SBP (mmHg) | 132.7 ± 19.8 | 135.5 ± 14.1 | 0.498 | | DBP (mmHg) | 78.9 ± 8.4 | 83.1 ± 12.1 | 0.065 | | HR (bpm) | 80 ± 11 | 79 ± 14 | 0.750 | | PWD (ms) | 44.9 ± 6.1 | 40.0 ± 5.5 | <0.001 |
|
|
PD, Parkinson’s disease; DM, diabetes mellitus; BMI, body mass index; BSA, body surface area; ASA, acetylsalicylic acid; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; OAD, oral antidiabetic; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; PWD, p-wave dispersion.
|
